Loading...
Market
What will be the impact of genomic testing on NHS patient care by end of 2025?
2
Oxford Nanopore Technologies•UK Government•Genomics England•UK Biobank•NHS England•Oxford Nanopore•UK
Resolution / Starting Odds
Significant Improvement • 25%
Moderate Improvement • 25%
No Change • 25%
Negative Impact • 25%
NHS England reports or independent evaluations
Story
Oxford Nanopore Partners with UK Government to Enhance Genomics-Driven Healthcare for 7,000 Samples in 6 Hours
Nov 5, 2024, 07:02 AM
Oxford Nanopore Technologies has announced a partnership with the UK Government, Genomics England, UK Biobank, and NHS England to enhance genomics-driven healthcare. This initiative aims to improve patient care, support biomedical research, and bolster pandemic preparedness through advanced genomic testing. The collaboration will also focus on rapid testing for severe respiratory infections, enabling healthcare providers to match patients with appropriate treatments within six hours. Additionally, researchers have utilized Oxford Nanopore's sequencing technology to analyze methylation profiles from 7,000 samples, uncovering novel structural variants at a population scale. This partnership signifies a major step forward in the application of next-generation sequencing technology in the UK healthcare system.
View original story
Similar markets
0-10 hospitals • 33%
11-20 hospitals • 33%
21+ hospitals • 34%
ADHD • 25%
Schizophrenia • 25%
Bipolar Disorder • 25%
Parkinson’s Disease • 25%
0-25% • 25%
26-50% • 25%
51-75% • 25%
76-100% • 25%
Yes • 50%
No • 50%
Full endorsement • 25%
Conditional endorsement • 25%
No endorsement • 25%
Opposition • 25%
Improved diagnostic accuracy • 25%
Reduced administrative workload • 25%
Addressed staffing shortages • 25%
Enhanced patient management • 25%
1-5 articles • 33%
6-10 articles • 33%
11+ articles • 34%
0-1000 • 25%
1001-5000 • 25%
5001-10000 • 25%
10001+ • 25%
Yes • 50%
No • 50%